美国食品药品监督管理局（FDA）已收到来自22nd Century集团的两份改良风险烟草产品（MRTP）续期申请，并已将其提交进行科学审查。此举标志着该公司在寻求维持其特定烟草产品作为“改良风险”类别销售资格方面迈出了关键一步。
改良风险烟草产品授权允许企业营销声称其产品对成年烟草使用者造成的危害或接触有害物质的风险低于传统烟草制品。此类申请的续期过程需要提供持续的科学证据，以支持原有的风险改良主张。
22nd Century此次提交续期申请，表明其致力于在监管框架内维持相关产品的市场地位。FDA的科学审查将全面评估公司提交的数据，以决定是否继续授权这些产品以改良风险类别进行销售。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.